

Jedd D Wolchok

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/822067/jedd-d-wolchok-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

230
papers

79,493
citations

101
h-index

251
g-index

251
ext. papers

98,842
ext. citations

18.1
avg, IF

8.17
L-index

#	Paper	IF	Citations
230	Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism.. <i>Science Advances</i> , 2022 , 8, eabm4552	14.3	0
229	Reply to T. Olivier et al.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200209	2.2	
228	Anatomic position determines oncogenic specificity in melanoma.. <i>Nature</i> , 2022 ,	50.4	3
227	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.. <i>Nature Communications</i> , 2022 , 13, 1935	17.4	3
226	Fundamental immune-oncogenicity trade-offs define driver mutation fitness.. <i>Nature</i> , 2022 ,	50.4	1
225	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. <i>Cancers</i> , 2022 , 14, 2638	6.6	2
224	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101570	2.2	2
223	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021 , 11, 1212-1227	12.7	29
222	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 2021 , 9,		2
221	Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer. <i>Communications Biology</i> , 2021 , 4, 1296	6.7	2
220	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study 2021 , 9,		6
219	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
218	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab 2021 , 9,		1
217	TNF in the era of immune checkpoint inhibitors: friend or foe?. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 213-223	8.1	26
216	Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9534-9534	2.2	1
215	CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. <i>Nature Medicine</i> , 2021 , 27, 1280-1289	50.5	103
214	CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9506-9506	2.2	29

213	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. <i>Nature Medicine</i> , 2021 , 27, 1646-1654	50.5	17
212	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021 , 184, 4032-4047.e346	36.2	25
211	Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8 T cells in tumors. <i>Immunity</i> , 2021 , 54, 1561-1577.e7	32.3	47
210	Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 577-578	8.1	
209	Tim-4 cavity-resident macrophages impair anti-tumor CD8 T cell immunity. <i>Cancer Cell</i> , 2021 , 39, 973-988.e9	24.9	13
208	Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. <i>Cell Reports</i> , 2021 , 34, 108620	10.6	6
207	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021 , 144, 182-191	7.5	23
206	CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer 2021 ,		11
205	CTLA-4 blockade drives loss of T stability in glycolysis-low tumours. <i>Nature</i> , 2021 , 591, 652-658	50.4	52
204	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	14
203	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021 , 9, 1202-1213	12.5	11
202	Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia 2021 , 9,		1
201	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4	42
200	Checkpoint blockade: the end of the beginning. <i>Nature Reviews Immunology</i> , 2021 , 21, 621	36.5	0
199	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021 , 157, 391-402	7.5	2
198	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. <i>OncImmunology</i> , 2021 , 10, 1898105	7.2	2
197	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. <i>Clinical Cancer Research</i> , 2021 , 27, 2226-2235	12.9	6
196	Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. <i>Cancer Discovery</i> , 2020 , 10, 1121-1128	24.4	156

195	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. <i>Nature Medicine</i> , 2020 , 26, 1114-1124	50.5	63
194	The future of cancer immunotherapy: microenvironment-targeting combinations. <i>Cell Research</i> , 2020 , 30, 507-519	24.7	194
193	Determinants of COVID-19 disease severity in patients with cancer. <i>Nature Medicine</i> , 2020 , 26, 1218-1223	30.5	329
192	Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors. <i>American Journal of Ophthalmology Case Reports</i> , 2020 , 19, 100799	1.3	2
191	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. <i>Nature Immunology</i> , 2020 , 21, 298-308	19.1	138
190	Intravitreal Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. <i>Ophthalmology</i> , 2020 , 127, 240-248	7.3	11
189	Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. <i>Melanoma Research</i> , 2020 , 30, 71-75	3.3	12
188	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1180-1188	3.1	21
187	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. <i>Nature Communications</i> , 2020 , 11, 4011	17.4	60
186	PD-L1 Blockade Therapy: Location, Location, Location. <i>Cancer Cell</i> , 2020 , 38, 615-617	24.3	3
185	The many faces of the anti-COVID immune response. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	314
184	Conserved Interferon- β Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020 , 38, 500-515.e3	24.3	75
183	Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Infectious Diseases</i> , 2020 , 70, 193-199	11.6	44
182	First-in-Humans Imaging with Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 512-519	8.9	86
181	Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?. <i>Cancer Cell</i> , 2019 , 36, 215-217	24.3	11
180	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
179	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. <i>Cell Reports</i> , 2019 , 27, 806-819.e5	10.6	25
178	Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019 , 25, 759-766	50.5	95

177	Immunotherapy of Melanoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019 , 25, 5191-5201	12.9	110
176	Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology. <i>European Journal of Cancer</i> , 2019 , 112, 29-31	7.5	12
175	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. <i>Cell</i> , 2019 , 178, 933-948.e14	56.2	141
174	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019 , 20, 1231-1243	19.1	132
173	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019 , 5, 1411-1420	13.4	216
172	Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma 2019 ,		12
171	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. <i>Journal of Clinical Investigation</i> , 2019 , 129, 3435-3447	15.9	24
170	Selective inhibition of low-affinity memory CD8 T cells by corticosteroids. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2701-2713	16.6	43
169	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. <i>Oncologist</i> , 2019 , 24, e196-e197	5.7	22
168	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019 , 5, 471-478	13.4	257
167	F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 335-341	8.9	78
166	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019 , 51, 202-206	36.3	1435
165	Prognostic value of baseline metabolic tumor volume measured on F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 930-939	8.8	43
164	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018 , 24, 4960-4967	12.9	142
163	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 1976-1986	59.2	865
162	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. <i>Cancer Cell</i> , 2018 , 33, 581-598	24.3	261
161	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018 , 33, 843-852.e4	24.3	525
160	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , 2018 , 173, 624-633.e8	56.2	71

159	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6cCD103 Monocytic Antigen-Presenting Cells in Tumors. <i>Immunity</i> , 2018 , 48, 91-106.e6	32.3	63
158	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2018 , 6, 189-200	12.5	84
157	Checkpoint Blockade 2018 , 37-53		
156	Shared cancer neoantigens: Making private matters public. <i>Journal of Experimental Medicine</i> , 2018 , 215, 5-7	16.6	27
155	Cancer immunotherapy using checkpoint blockade. <i>Science</i> , 2018 , 359, 1350-1355	33.3	2480
154	Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. <i>Molecular Therapy</i> , 2018 , 26, 1008-1019	11.7	62
153	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	227
152	Refusing to TAP out: 16 new human TEIPPs identified. <i>Journal of Experimental Medicine</i> , 2018 , 215, 2233-2234		
151	Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. <i>Cancer Discovery</i> , 2018 , 8, 1006-1025	24.4	141
150	Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018 , 33, 1017-1032.e7	24.3	81
149	PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1413-1428	15.9	79
148	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. <i>Oncotarget</i> , 2018 , 9, 28702-28716	3.3	14
147	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018 , 4, 98-101	13.4	98
146	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 391-398	2.2	118
145	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1685-1694	2.3	274
144	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 850-858	2.2	184
143	Putting the Immunologic Brakes on Cancer. <i>Cell</i> , 2018 , 175, 1452-1454	56.2	39
142	Acquired resistance to immunotherapy in MMR-D pancreatic cancer 2018 , 6, 127		19

141	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1480-1492	21.7	680
140	The hallmarks of successful anticancer immunotherapy. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	260
139	Strategies for Predicting Response to Checkpoint Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2018 , 13, 383-395	4.4	17
138	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018 , 8, 822-835	24.4	648
137	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 226-235	2.2	302
136	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology, The</i> , 2017 , 18, e143-e152	21.7	1010
135	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017 , 73, 61-70	7.5	59
134	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. <i>Nature Communications</i> , 2017 , 8, 14340	17.4	80
133	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. <i>EBioMedicine</i> , 2017 , 18, 56-61	8.8	67
132	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017 , 545, 60-65	50.4	850
131	Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017 , 25, 2155-2167	3.9	7
130	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <i>Nature</i> , 2017 , 545, 452-456	45.4	413
129	Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. <i>Science Immunology</i> , 2017 , 2,	28	66
128	Curbing TregsR(Lack of) Enthusiasm. <i>Cell</i> , 2017 , 169, 981-982	56.2	4
127	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	41
126	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 785-792	2.2	696
125	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. <i>Modern Pathology</i> , 2017 , 30, 599-609	9.8	43
124	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2017 , 5, 84-91	12.5	70

123	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology, The</i> , 2017 , 18, e653-e706	21.7	106
122	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment 2017 , 5, 76		78
121	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3807-3814	2.2	264
120	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3815-3822	2.2	160
119	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. <i>Cell</i> , 2017 , 170, 927-938.e20	56.2	267
118	Blockade of surface-bound TGF- β 1n regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. <i>Science Signaling</i> , 2017 , 10,	8.8	69
117	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
116	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. <i>Nature</i> , 2017 , 551, 512-516	50.4	533
115	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. <i>Nature</i> , 2017 , 551, 517-520	50.4	336
114	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017 , 82, 80-91	7.5	55
113	Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial 2017 ,		5
112	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , 2016 , 4, 835-844	12.5	95
111	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016 , 122, 3354-3362	6.4	164
110	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1558-1568	21.7	627
109	Overcoming resistance to checkpoint blockade therapy by targeting PI3K α in myeloid cells. <i>Nature</i> , 2016 , 539, 443-447	50.4	475
108	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. <i>Science Translational Medicine</i> , 2016 , 8, 328rv4	17.5	1281
107	Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?. <i>Cancer Discovery</i> , 2016 , 6, 1210-1211	24.4	10
106	RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016 , 62, 138-45	7.5	117

105	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials 2016 , 4, 15		47
104	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016 , 21, 848-54	5.7	115
103	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1048929	1.2	24
102	Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. <i>Immunity</i> , 2016 , 44, 179-193	32.3	25
101	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 2908-18	12.9	372
100	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. <i>Nature Communications</i> , 2016 , 7, 10391	17.4	524
99	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 273-90	19.4	640
98	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1510-7	2.2	509
97	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 1364-70	12.9	182
96	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. <i>EBioMedicine</i> , 2016 , 6, 50-58	8.8	86
95	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016 , 351, 1463-9	33.3	1758
94	First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3017-3017	2.2	26
93	Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer. <i>Blood</i> , 2016 , 128, 861-861	2.2	
92	Proportions of blood-borne V α 1+ and V α 2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2016 , 64, 116-26	7.5	36
91	Reply to A. Indini et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1018-9	2.2	
90	Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. <i>Experimental Dermatology</i> , 2016 , 25, 553-4	4	11
89	RECIST 1.1-Update and clarification: From the RECIST committee. <i>European Journal of Cancer</i> , 2016 , 62, 132-7	7.5	607
88	Patient-Physician Communication in the 21st Century. <i>Trends in Immunology</i> , 2016 , 37, 347-349	14.4	1

87	Targeting T Cell Co-receptors for Cancer Therapy. <i>Immunity</i> , 2016 , 44, 1069-78	32.3	314
86	Combinatorial Cancer Immunotherapies. <i>Advances in Immunology</i> , 2016 , 130, 251-77	5.6	75
85	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016 , 22, 5487-5496	12.9	373
84	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016 , 4, 383-9	12.5	199
83	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1600-9	27.4	666
82	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. <i>Oncotmunology</i> , 2016 , 5, e1151595	7.2	39
81	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 4848-4858	12.9	108
80	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. <i>Cancer Immunology Research</i> , 2016 , 4, 936-947	12.5	82
79	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4102-4109	2.2	400
78	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. <i>Clinical Cancer Research</i> , 2015 , 21, 2289-96	12.9	90
77	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. <i>JAMA Oncology</i> , 2015 , 1, 433-40	13.4	160
76	The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. <i>Advances in Cancer Research</i> , 2015 , 128, 1-68	5.9	34
75	Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. <i>New England Journal of Medicine</i> , 2015 , 372, 2073-4	59.2	47
74	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. <i>New England Journal of Medicine</i> , 2015 , 372, 2006-17	59.2	2001
73	Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015 , 348, 124-8	33.3	5003
72	On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. <i>Science Translational Medicine</i> , 2015 , 7, 280sr1	17.5	113
71	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1889-94	2.2	1425
70	Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1191-6	2.2	334

69	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 1270-1	59.2	631
68	Genetics and immunology: reinvigorated. <i>OncImmunity</i> , 2015 , 4, e1029705	7.2	7
67	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. <i>Oncologist</i> , 2015 , 20, 648-52	5.7	28
66	Safety of Infusing Ipilimumab Over 30 Minutes. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3454-8	2.2	19
65	Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. <i>Nature Communications</i> , 2015 , 6, 6840	17.4	56
64	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. <i>Cell Reports</i> , 2015 , 13, 412-24	10.6	275
63	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3193-8	2.2	697
62	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <i>Cell</i> , 2015 , 162, 974-86	56.2	872
61	PD-1 Blockers. <i>Cell</i> , 2015 , 162, 937	56.2	95
60	Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma 2015 , 3, 23		134
59	Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 368-75	4	268
58	Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. <i>Seminars in Oncology</i> , 2015 , 42, 573-86	5.5	17
57	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
56	The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. <i>Science Advances</i> , 2015 , 1, e1500845	14.3	113
55	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015 , 25, 208-24	24.7	126
54	Immune Checkpoint Blockade in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1974-82	2.2	1690
53	The importance of animal models in tumor immunity and immunotherapy. <i>Current Opinion in Genetics and Development</i> , 2014 , 24, 46-51	4.9	49
52	Immune modulation in cancer with antibodies. <i>Annual Review of Medicine</i> , 2014 , 65, 185-202	17.4	366

51	Ipilimumab in patients with cancer and the management of dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 161-9	4.5	142
50	Immune checkpoint blockade. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 585-600	3.1	57
49	Potential of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. <i>Molecular Therapy - Oncolytics</i> , 2014 , 1, 14004	6.4	28
48	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. <i>Frontiers in Oncology</i> , 2014 , 4, 385	5.3	135
47	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
46	Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. <i>Cancer Immunology Research</i> , 2014 , 2, 448-58	12.5	27
45	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1056-64	14.4	146
44	Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. <i>Cancer Immunology Research</i> , 2014 , 2, 812-21	12.5	97
43	Genetic basis for clinical response to CTLA-4 blockade in melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 2189-2199	59.2	2802
42	Cancer: Antitumour immunity gets a boost. <i>Nature</i> , 2014 , 515, 496-8	50.4	77
41	Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. <i>Science Translational Medicine</i> , 2014 , 6, 226ra32	17.5	484
40	Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2397-405	27.4	285
39	Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. <i>Cancer Immunology Research</i> , 2014 , 2, 70-9	12.5	80
38	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy 2014 , 2, 7		85
37	Ipilimumab in patients with melanoma and autoimmune disease 2014 , 2, 35		70
36	Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma. <i>Methods in Molecular Biology</i> , 2014 , 1102, 83-95	1.4	6
35	Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. <i>Investigational New Drugs</i> , 2013 , 31, 425-34	4.3	105
34	GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. <i>Cancer Immunology Research</i> , 2013 , 1, 320-31	12.5	114

33	The abscopal effect associated with a systemic anti-melanoma immune response. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 85, 293-5	4	304
32	Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. <i>Cancer Immunology Research</i> , 2013 , 1, 235-44	12.5	75
31	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. <i>Journal of Experimental Medicine</i> , 2013 , 210, 1695-710	16.6	948
30	The delicate balance of melanoma immunotherapy. <i>Clinical and Translational Immunology</i> , 2013 , 2, e5	6.8	21
29	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. <i>Journal of Experimental Medicine</i> , 2013 , 210, 1389-402	16.6	452
28	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma 2013 , 1, 20		27
27	Enhanced responses to tumor immunization following total body irradiation are time-dependent. <i>PLoS ONE</i> , 2013 , 8, e82496	3.7	10
26	Alan Houghton. <i>Pigment Cell and Melanoma Research</i> , 2012 , 25, 401	4.5	
25	Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. <i>Cancer Cell</i> , 2012 , 22, 668-82	24.3	377
24	Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. <i>Cancer Research</i> , 2012 , 72, 876-86	10.1	264
23	Modulation of GITR for cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2012 , 24, 217-24	7.8	112
22	Immunologic correlates of the abscopal effect in a patient with melanoma. <i>New England Journal of Medicine</i> , 2012 , 366, 925-31	59.2	1503
21	Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. <i>Journal of Experimental Medicine</i> , 2012 , 209, 2113-26	16.6	97
20	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. <i>New England Journal of Medicine</i> , 2011 , 364, 2517-26	59.2	3396
19	Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. <i>PLoS ONE</i> , 2011 , 6, e21214	3.7	12
18	KIT as a therapeutic target in metastatic melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 2327-34	27.4	619
17	Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. <i>PLoS ONE</i> , 2010 , 5, e10436	3.7	194
16	Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. <i>PLoS ONE</i> , 2010 , 5, e12670	3.7	46

15	Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. <i>Clinical Cancer Research</i> , 2010 , 16, 2861-71	12.9	347
14	Improved survival with ipilimumab in patients with metastatic melanoma. <i>New England Journal of Medicine</i> , 2010 , 363, 711-23	59.2	10591
13	Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. <i>Lancet Oncology, The</i> , 2010 , 11, 155-64	21.7	910
12	Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. <i>Clinical Cancer Research</i> , 2009 , 15, 7412-20	12.9	2380
11	OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1103-16	16.6	174
10	Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. <i>Journal of Experimental Medicine</i> , 2009 , 206, 849-66	16.6	85
9	The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. <i>Oncologist</i> , 2008 , 13 Suppl 4, 2-9	5.7	178
8	Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. <i>Molecular Therapy</i> , 2007 , 15, 2044-50	11.7	82
7	Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. <i>Cancer Research</i> , 2006 , 66, 4904-12	10.1	179
6	DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).. <i>Blood</i> , 2004 , 104, 304-304	2.2	
5	DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution.. <i>Blood</i> , 2004 , 104, 3057-3057	2.2	
4	Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. <i>Melanoma Research</i> , 2003 , 13, 189-96	3.3	35
3	DNA vaccines: an active immunization strategy for prostate cancer. <i>Seminars in Oncology</i> , 2003 , 30, 659-665	9.5	41
2	Coupling and uncoupling of tumor immunity and autoimmunity. <i>Journal of Experimental Medicine</i> , 1999 , 190, 1717-22	16.6	214
1	Oxidized Lipids and CD36-Mediated Lipid Peroxidation in CD8 T Cells Suppress Anti-Tumor Immune Responses 2		